J Budczies1, M Allgäuer2, K Litchfield3, E Rempel2, P Christopoulos4, D Kazdal5, V Endris2, M Thomas4, S Fröhling6, S Peters7, C Swanton3, P Schirmacher8, A Stenzinger9. 1. Institute of Pathology, University Hospital Heidelberg, Heidelberg; German Cancer Consortium (DKTK), Partner Site Heidelberg, Heidelberg, Germany. Electronic address: jan.budczies@med.uni-heidelberg.de. 2. Institute of Pathology, University Hospital Heidelberg, Heidelberg. 3. Cancer Evolution and Genome Instability Translational Cancer Therapeutics Laboratory, Francis Crick Institute, London, UK. 4. Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg; German Center for Lung Research (DZL), Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg. 5. Institute of Pathology, University Hospital Heidelberg, Heidelberg; German Center for Lung Research (DZL), Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg. 6. Department of Translational Oncology, National Center for Tumor Diseases (NCT), Heidelberg; German Cancer Research Center (DKFZ), Heidelberg, Germany. 7. Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University, Switzerland. 8. Institute of Pathology, University Hospital Heidelberg, Heidelberg; German Cancer Consortium (DKTK), Partner Site Heidelberg, Heidelberg, Germany. 9. Institute of Pathology, University Hospital Heidelberg, Heidelberg; German Cancer Consortium (DKTK), Partner Site Heidelberg, Heidelberg, Germany. Electronic address: albrecht.stenzinger@med.uni-heidelberg.de.
Abstract
BACKGROUND: Panel sequencing based estimates of tumor mutational burden (psTMB) are increasingly replacing whole exome sequencing (WES) tumor mutational burden as predictive biomarker of immune checkpoint blockade (ICB). DESIGN: A mathematical law describing psTMB variability was derived using a random mutation model and complemented by the contributions of non-randomly mutated real-world cancer genomes and intratumoral heterogeneity through simulations in publicly available datasets. RESULTS: The coefficient of variation (CV) of psTMB decreased inversely proportional with the square root of the panel size and the square root of the TMB level. In silico simulations of all major commercially available panels in the TCGA pan-cancer cohort confirmed the validity of this mathematical law and demonstrated that the CV was 35% for TMB = 10 muts/Mbp for the largest panels of size 1.1-1.4 Mbp. Accordingly, misclassification rates (gold standard: WES) to separate 'TMBhigh' from 'TMBlow' using a cut-point of 199 mutations were 10%-12% in TCGA-LUAD and 17%-19% in TCGA-LUSC. A novel three-tier psTMB classification scheme which accounts for the likelihood of misclassification is proposed. Simulations in two WES datasets of immunotherapy treated patients revealed that small gene panels were poor predictors of ICB response. Moreover, we noted substantial intratumoral variance of psTMB scores in the TRACERx 100 cohort and identified indel burden as independent marker complementing missense mutation burden. CONCLUSIONS: A universal mathematical law describes accuracy limitations inherent to psTMB, which result in substantial misclassification rates. This scenario can be controlled by two measures: (i) a panel design that is based on the mathematical law described in this article: halving the CV requires a fourfold increase in panel size, (ii) a novel three-tier TMB classification scheme. Moreover, inclusion of indel burden can complement TMB reports. This work has substantial implications for panel design, TMB testing, clinical trials and patient management.
BACKGROUND: Panel sequencing based estimates of tumor mutational burden (psTMB) are increasingly replacing whole exome sequencing (WES) tumor mutational burden as predictive biomarker of immune checkpoint blockade (ICB). DESIGN: A mathematical law describing psTMB variability was derived using a random mutation model and complemented by the contributions of non-randomly mutated real-world cancer genomes and intratumoral heterogeneity through simulations in publicly available datasets. RESULTS: The coefficient of variation (CV) of psTMB decreased inversely proportional with the square root of the panel size and the square root of the TMB level. In silico simulations of all major commercially available panels in the TCGA pan-cancer cohort confirmed the validity of this mathematical law and demonstrated that the CV was 35% for TMB = 10 muts/Mbp for the largest panels of size 1.1-1.4 Mbp. Accordingly, misclassification rates (gold standard: WES) to separate 'TMBhigh' from 'TMBlow' using a cut-point of 199 mutations were 10%-12% in TCGA-LUAD and 17%-19% in TCGA-LUSC. A novel three-tier psTMB classification scheme which accounts for the likelihood of misclassification is proposed. Simulations in two WES datasets of immunotherapy treated patients revealed that small gene panels were poor predictors of ICB response. Moreover, we noted substantial intratumoral variance of psTMB scores in the TRACERx 100 cohort and identified indel burden as independent marker complementing missense mutation burden. CONCLUSIONS: A universal mathematical law describes accuracy limitations inherent to psTMB, which result in substantial misclassification rates. This scenario can be controlled by two measures: (i) a panel design that is based on the mathematical law described in this article: halving the CV requires a fourfold increase in panel size, (ii) a novel three-tier TMB classification scheme. Moreover, inclusion of indel burden can complement TMB reports. This work has substantial implications for panel design, TMB testing, clinical trials and patient management.
Authors: Hyung-Don Kim; Min-Hee Ryu; Young Soo Park; Sun Young Lee; Meesun Moon; Yoon-Koo Kang Journal: Gastric Cancer Date: 2021-09-01 Impact factor: 7.370
Authors: Binsheng Gong; Dan Li; Rebecca Kusko; Natalia Novoradovskaya; Yifan Zhang; Shangzi Wang; Carlos Pabón-Peña; Zhihong Zhang; Kevin Lai; Wanshi Cai; Jennifer S LoCoco; Eric Lader; Todd A Richmond; Vinay K Mittal; Liang-Chun Liu; Donald J Johann; James C Willey; Pierre R Bushel; Ying Yu; Chang Xu; Guangchun Chen; Daniel Burgess; Simon Cawley; Kristina Giorda; Nathan Haseley; Fujun Qiu; Katherine Wilkins; Hanane Arib; Claire Attwooll; Kevin Babson; Longlong Bao; Wenjun Bao; Anne Bergstrom Lucas; Hunter Best; Ambica Bhandari; Halil Bisgin; James Blackburn; Thomas M Blomquist; Lisa Boardman; Blake Burgher; Daniel J Butler; Chia-Jung Chang; Alka Chaubey; Tao Chen; Marco Chierici; Christopher R Chin; Devin Close; Jeffrey Conroy; Jessica Cooley Coleman; Daniel J Craig; Erin Crawford; Angela Del Pozo; Ira W Deveson; Daniel Duncan; Agda Karina Eterovic; Xiaohui Fan; Jonathan Foox; Cesare Furlanello; Abhisek Ghosal; Sean Glenn; Meijian Guan; Christine Haag; Xinyi Hang; Scott Happe; Brittany Hennigan; Jennifer Hipp; Huixiao Hong; Kyle Horvath; Jianhong Hu; Li-Yuan Hung; Mirna Jarosz; Jennifer Kerkhof; Benjamin Kipp; David Philip Kreil; Paweł Łabaj; Pablo Lapunzina; Peng Li; Quan-Zhen Li; Weihua Li; Zhiguang Li; Yu Liang; Shaoqing Liu; Zhichao Liu; Charles Ma; Narasimha Marella; Rubén Martín-Arenas; Dalila B Megherbi; Qingchang Meng; Piotr A Mieczkowski; Tom Morrison; Donna Muzny; Baitang Ning; Barbara L Parsons; Cloud P Paweletz; Mehdi Pirooznia; Wubin Qu; Amelia Raymond; Paul Rindler; Rebecca Ringler; Bekim Sadikovic; Andreas Scherer; Egbert Schulze; Robert Sebra; Rita Shaknovich; Qiang Shi; Tieliu Shi; Juan Carlos Silla-Castro; Melissa Smith; Mario Solís López; Ping Song; Daniel Stetson; Maya Strahl; Alan Stuart; Julianna Supplee; Philippe Szankasi; Haowen Tan; Lin-Ya Tang; Yonghui Tao; Shraddha Thakkar; Danielle Thierry-Mieg; Jean Thierry-Mieg; Venkat J Thodima; David Thomas; Boris Tichý; Nikola Tom; Elena Vallespin Garcia; Suman Verma; Kimbley Walker; Charles Wang; Junwen Wang; Yexun Wang; Zhining Wen; Valtteri Wirta; Leihong Wu; Chunlin Xiao; Wenzhong Xiao; Shibei Xu; Mary Yang; Jianming Ying; Shun H Yip; Guangliang Zhang; Sa Zhang; Meiru Zhao; Yuanting Zheng; Xiaoyan Zhou; Christopher E Mason; Timothy Mercer; Weida Tong; Leming Shi; Wendell Jones; Joshua Xu Journal: Genome Biol Date: 2021-04-16 Impact factor: 13.583
Authors: Dan Sha; Zhaohui Jin; Jan Budczies; Klaus Kluck; Albrecht Stenzinger; Frank A Sinicrope Journal: Cancer Discov Date: 2020-11-02 Impact factor: 38.272